期刊文献+

冠心病患者单核源巨噬细胞体外分泌的基质金属蛋白酶-9、组织因子临床意义的探讨

The clinical significance of matrix metalloproteinase-9 and tissue factor secreted by monocyte derived-macrophages in vitro in coronary heart disease
暂未订购
导出
摘要 目的探讨单核源巨噬细胞分泌的基质金属蛋白酶-9(MMP-9)、组织因子(TF)在冠心病中的临床意义。方法密度梯度离心法提取12名急性心肌梗死(AM I)、16名不稳定心绞痛(UAP)、12名稳定型心绞痛(SAP)患者和8名冠脉正常者(Norm)的单核细胞,用佛波酯诱导其分化为巨噬细胞,ELISA法测定单核源巨噬细胞上清液MMP-9、TF含量。结果AM I、UAP组单核源巨噬细胞体外分泌MMP-9、TF的含量明显高于SAP、Norm组(P<0.05和<0.01),但AM I与UAP组间、SAP与Norm组间均无统计学差异,且MMP-9、TF含量与年龄、冠脉病变积分无统计学相关,在不同冠心病危险因素组间(0、1-2、3-4、4个以上危险因素)亦无统计学差异。结论单核源巨噬细胞体外分泌MMP-9、TF可作为急性冠脉综合征(ACS)病情评估的参考指标。 Objective To investigate the clinical significance of matrix metalloproteinase - 9 (MMP - 9) and tissue factor (TF) secreted by monocyte derived- macrephages in vitro in coronary heart disease (CHD). Methods Monocytes in peripheral blood were obtained from 12 patients with acute myocardial infarction( AMI), 16 unstable angina pectoris (UAP),12 stable angina pectoris (SAP) and 8 normals (Norm) by ficoll density gradient centrifugalization. The cells were incubated for 48 hours to induce them to differentiate into macrephages by adding phorbolester 12 - myristate 13 - acetate (PMA). The levels of MMP - 9 and TF in the supematant were measured by ELISA. Results It was found that the levels of MMP -9 and TF were significantly higher in AMI and UAP groups than those in SAP and Norm groups (P 〈0.05 and P 〈0.01 respectively). But there were no significant differences in them between AMI group and UAP group,or between SAP group and Norm group. Moreover, nor were there any statistical differences in the levels of MMP -9 and TF among the different CHD risk factor ranks(0, 1 -2, 3 -4 and more than 4 risk factors), or any correlation of the MMP - 9 and TF levels to the age and the coronary artery score. Conclusion The levels of MMP - 9 and TF secreted by macrephages in patients with CHD in vitro could be referred to as an index to estimate the condition of acute coronary syndrome (ACS).
出处 《徐州医学院学报》 CAS 2007年第2期74-77,共4页 Acta Academiae Medicinae Xuzhou
基金 江苏省中医药管理局资助课题(H05105)
关键词 冠心病 单核源巨噬细胞 基质金属蛋白酶-9 组织因子 coronary heart disease monocyte -derived macrophages matrix metalloproteinase -9 tissue factor
  • 相关文献

参考文献10

  • 1Strike PC, Magid K, Whitehead DL, et al. Pathophysiological proccesses underlying emotional triggering of acute cardiac events[J]. Proc Nad Acad Sci USA, 2006,103(11) : 4322 -4327.
  • 2Carter AM. Inflammation, thrombosis and acute coronary syndromes[J]. Diab Vasc Dis Res, 2005, 2(3) : 113 -121.
  • 3Tziakas DN, Chalikias GK, Parissis JT, et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short - term atorvastatin administration [ J ]. Int J Cardiol, 2004, 94 (2 - 3 ) : 269 - 277.
  • 4方崇峰,陈样新,傅国胜.基质金属蛋白酶-9与急性冠状动脉综合征的临床相关性研究[J].临床心血管病杂志,2005,21(3):150-152. 被引量:4
  • 5Virmani R, Burke AP, Farb A, et al. Pathology of the vulnerable plaque[J]. J Am Coll Cardiol, 2006, 47(8 Suppl) : C13 -18.
  • 6Jude B, Zawadzki C, Susen S, et al. Relevance of tissue factor in cardiovascular disease[J]. Arch Mal Coeur Vaiss, 2005, 98(6) :667 - 671.
  • 7Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis[J]. Blood, 2000, 96(3) : 966 -972.
  • 8Zaman AG, Helft G, Worthley SG, et al. The role of plaque rupture and thrombosis in coronary artery disease [ J ]. Atherosclerosis,2000, 149(2): 251 -266.
  • 9Moons AH, Levi M, Peters RJ. Tissue factor and coronary artery disease[J]. Cardiovasc Res, 2002, 53(2): 313-325.
  • 10Inokubo Y, Hanada H, Ishizaka H,et al. Plasma levels of matrix metalloproteinase -9 and tissue inhibitor of metalloproteinase - 1 are increased in the coronary circulation in patients with acute coronary syndrome[J]. Am Heart J, 2001, 141(2) : 211 -217.

二级参考文献9

  • 1Picketing J G,Ford C M,Tang B,et al.Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens,matrix metalloproteinases by human vascular smooth muscle ceIIs.Evidence for repressed collagen production and activated degradative capacity.Arterioscler Thromb Vase Biol ,1997,17:475-482.
  • 2Shu Y E,Humphries S,Henney A.Matrix metalloproteinases:implication in vascular matrix remodeling during atherogenesis.Clin Sci ,1998,94:103-110.
  • 3Foda H D,George S,Rollo E,et al.Regulation of gelatinases in human airway smooth muscle cells:mechanism of progelatinase A activation.Am J Physiol ,1999,277:174-1 82.
  • 4Uzui H,Lee J D,Shimizu H,et al.The role of protein-tyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells.Atherosclerosis, 2000,149:51-59.
  • 5Kai H,Ikeda H,Yasukawa H,et al. Peripheril blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes.Am Coll Cardial,1998,32:368-372.
  • 6Rajagopalan S,Meng X P, Ramasamy S,et a1.Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro:Implications for atherosclerotic plaque stability.J Clin Invest,1996,98:2572-2579.
  • 7Nomoto K,Oguchi S,Watanabe I,et a1.Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vasctdar-cell adhesion molecule-1.J Cardiol,2003,42:201-206.
  • 8Tziakas D N,Chalikias G K.Parissis J T,et a1. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes.The effects of short-term atorvastatin administration.Int J Cardiol,2004,94 :269-277.
  • 9Eckart R E,Uyehara C F,Shry E A,et al. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization,J Interv Cardiol ,2004,17:27-31.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部